- Home
- IDYA vs CERT Comparison
IDYA vs CERT Comparison
Compare IDYA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- CERT
- Stock Information
- Founded
- IDYA 2015
- CERT 2008
- Country
- IDYA United States
- CERT United States
- Employees
- IDYA N/A
- CERT N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- IDYA Health Care
- CERT Technology
- Exchange
- IDYA Nasdaq
- CERT Nasdaq
- Market Cap
- IDYA 1.9B
- CERT 1.7B
- IPO Year
- IDYA 2019
- CERT 2020
- Fundamental
- Price
- IDYA $21.23
- CERT $11.70
- Analyst Decision
- IDYA Strong Buy
- CERT Buy
- Analyst Count
- IDYA 13
- CERT 6
- Target Price
- IDYA $53.42
- CERT $15.60
- AVG Volume (30 Days)
- IDYA 1.1M
- CERT 2.0M
- Earning Date
- IDYA 08-05-2025
- CERT 08-05-2025
- Dividend Yield
- IDYA N/A
- CERT N/A
- EPS Growth
- IDYA N/A
- CERT N/A
- EPS
- IDYA N/A
- CERT N/A
- Revenue
- IDYA $7,000,000.00
- CERT $394,498,000.00
- Revenue This Year
- IDYA $101.20
- CERT $11.57
- Revenue Next Year
- IDYA $286.70
- CERT $8.93
- P/E Ratio
- IDYA N/A
- CERT N/A
- Revenue Growth
- IDYA N/A
- CERT 9.37
- 52 Week Low
- IDYA $13.45
- CERT $8.64
- 52 Week High
- IDYA $44.42
- CERT $16.93
- Technical
- Relative Strength Index (RSI)
- IDYA 62.23
- CERT 55.84
- Support Level
- IDYA $21.08
- CERT $10.23
- Resistance Level
- IDYA $22.37
- CERT $12.41
- Average True Range (ATR)
- IDYA 0.92
- CERT 0.50
- MACD
- IDYA -0.09
- CERT 0.09
- Stochastic Oscillator
- IDYA 61.72
- CERT 67.40
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.